Linear Diagnostics
Linear Diagnostics Limited is dedicated to delivering enhanced diagnostic solutions through novel technology, focusing on rapid, accurate, and cost-effective point-of-care testing for infectious diseases, especially sexually transmitted infections. The company utilizes proprietary linear dichroism and EXPAR technologies to enable rapid detection of multiple targets with disposable cartridges on low-cost instruments, aiming to improve healthcare outcomes and reduce costs.
Industries
Nr. of Employees
small (1-50)
Linear Diagnostics
BioHub Birmingham, 97 Vincent Drive Birmingham, B15 2SQ
Products
Dual nucleic-acid rapid point-of-care test for chlamydia and gonorrhoea
A duplex nucleic-acid test designed to detect gene sequences specific to Chlamydia trachomatis and Neisseria gonorrhoeae from a single sample, providing a rapid time-to-result (~15–20 minutes) using a disposable cartridge and portable reader to enable same-visit diagnosis and treatment.
Rapid SARS‑CoV‑2 IgM/IgG antibody test with compact reader and digital certificate
A 15‑minute point-of-care antibody test that provides separate IgM and IgG results from finger‑stick whole blood, uses a compact reader to provide quantified results (Negative/Weak/Moderate/Strong) and stores a digital antibody certificate on a smartphone.
Rapid SARS‑CoV‑2 antigen nasal-swab test
A minimally invasive nasal-swab antigen test with a ~20 minute time-to-result and reported performance against known variants.
Portfolio of rapid POC tests for infectious diseases (HIV, syphilis, Zika, Ebola)
A set of rapid point-of-care tests for various infectious diseases offered via distribution agreements.
Dual nucleic-acid rapid point-of-care test for chlamydia and gonorrhoea
A duplex nucleic-acid test designed to detect gene sequences specific to Chlamydia trachomatis and Neisseria gonorrhoeae from a single sample, providing a rapid time-to-result (~15–20 minutes) using a disposable cartridge and portable reader to enable same-visit diagnosis and treatment.
Rapid SARS‑CoV‑2 IgM/IgG antibody test with compact reader and digital certificate
A 15‑minute point-of-care antibody test that provides separate IgM and IgG results from finger‑stick whole blood, uses a compact reader to provide quantified results (Negative/Weak/Moderate/Strong) and stores a digital antibody certificate on a smartphone.
Rapid SARS‑CoV‑2 antigen nasal-swab test
A minimally invasive nasal-swab antigen test with a ~20 minute time-to-result and reported performance against known variants.
Portfolio of rapid POC tests for infectious diseases (HIV, syphilis, Zika, Ebola)
A set of rapid point-of-care tests for various infectious diseases offered via distribution agreements.
Services
Collaborative development relationships to co-develop disposable cartridges and portable reader hardware for near-patient tests.
Distribution and customer support for CE‑IVD rapid antigen and antibody tests including SARS-CoV-2 assays in specified territories.
Research and development services to translate detection chemistry into disposable cartridges and compact reader instruments suitable for point-of-care deployment.
Collaborative development relationships to co-develop disposable cartridges and portable reader hardware for near-patient tests.
Distribution and customer support for CE‑IVD rapid antigen and antibody tests including SARS-CoV-2 assays in specified territories.
Research and development services to translate detection chemistry into disposable cartridges and compact reader instruments suitable for point-of-care deployment.
Expertise Areas
- Point-of-care diagnostic development
- Nucleic acid amplification assays (isothermal)
- Optical biosensor design using polarised light
- Multiplex assay design
Key Technologies
- Linear dichroism (polarised-light) detection
- EXPAR isothermal nucleic acid amplification
- Disposable self-sampling cartridge
- Visible‑dye based optical multiplexing
News & Updates
Linear Diagnostics Limited (LDL) has appointed Paul Thompson of Capel Thompson and Homer to seek potential partners to co-develop and market their Point of Care test for Chlamydia and Gonorrhoea which utilises the company’s proprietary Linear Dichroism technology.
The news article discusses the development of rapid tests for gonorrhoea and chlamydia by the University of Birmingham spinout, Linear Diagnostics, which has raised £2m to develop these diagnostic tools.
Linear Diagnostics Limited, a spin-out from the University of Birmingham, has secured £2m of investment to develop a platform technology for rapid diagnostic testing, targeting sexually transmitted diseases.
Linear Diagnostics has gained a £2m funding package to develop a rapid STI test capable of detecting infections from a single sample, enabling diagnosis and treatment in a single patient visit.
Linear Diagnostics Limited (LDL) has appointed Paul Thompson of Capel Thompson and Homer to seek potential partners to co-develop and market their Point of Care test for Chlamydia and Gonorrhoea which utilises the company’s proprietary Linear Dichroism technology.
The news article discusses the development of rapid tests for gonorrhoea and chlamydia by the University of Birmingham spinout, Linear Diagnostics, which has raised £2m to develop these diagnostic tools.
Linear Diagnostics Limited, a spin-out from the University of Birmingham, has secured £2m of investment to develop a platform technology for rapid diagnostic testing, targeting sexually transmitted diseases.
Linear Diagnostics has gained a £2m funding package to develop a rapid STI test capable of detecting infections from a single sample, enabling diagnosis and treatment in a single patient visit.